...
首页> 外文期刊>Regulatory Mechanisms in Biosystems >Pharmacological correction of the hemostasis system for the surgical treatment of bitches with tumours of the mammary gland
【24h】

Pharmacological correction of the hemostasis system for the surgical treatment of bitches with tumours of the mammary gland

机译:止血系统的药理校正,用于乳腺肿瘤母犬的外科手术治疗

获取原文
   

获取外文期刊封面封底 >>

       

摘要

We carried out the clinical validation of pathogenetically substantiated protocols for the treatment of female dogs with tumour lesions of the mammary gland. The positive effect of corrective therapy was characterized by a decrease in the physiological level of fibrinogen: in benign tumours in 10 days, malignant – in 14 days against the background of its stable high level in control animals with malignant neoplasia. In the postoperative period in experimental animals, the functioning of the internal coagulation unit was restored, as evidenced by the normalization of the activated partial thromboplastin time for benign tumours by days 10–14, malignant – by 14 days. In control patients, these changes were detected only for benign neoplasms. Shifts of the external mechanism of blood coagulation in the experimental groups were eliminated in benign neoplasia cases in 10 days, malignant cases in 14 days against the background of severe disorders in this link in control patients throughout the observation period. The positive effect of complex treatment regimens is confirmed by the restoration of total fibrinolytic activity by days 10–14 due to the normalization in the same terms of the plasminogen activator and tissue plasminogen activator by days 3–7. In control animals, the total fibrinolytic activity was consistent with those of clinically healthy animals only for benign neoplasms. The balancing of coagulation and fibrinolytic mechanisms was accompanied by a decrease in the activity of proteolytic inhibitors: α2-macroglobulin in experimental groups with benign neoplasia by day 10, malignant – by days 10–14, and control – respectively, by days 3 and 14; α1-proteinase inhibitor in all groups by day 3. Concentration of nitric oxide after extirpation of benign tumors already at day 3 of the postoperative period in all groups corresponded to the indexes of clinically healthy dogs, with the removal of malignant tumours – in experimental animals at day 3, control – at day 14. The content of malondialdehyde and ceruloplasmin against the background of pharmacological correction was restored by days 10–14, whereas in control animals – only with benign neoplasms by day 14. Postoperative pharmacological correction of the hemostasis system can significantly improve the results of treatment in cancer patients.
机译:我们进行了病原学证实的方案的临床验证,用于治疗患有乳腺肿瘤的雌性狗。纠正疗法的积极作用的特征在于,纤维蛋白原的生理水平降低:在良性肿瘤中,恶性肿瘤形成的对照动物在稳定状态下,在10天内恶变–在14天内达到稳定水平。在实验动物的术后期,内部凝血单位的功能得以恢复,良性肿瘤的活化部分凝血活酶时间正常化为10-14天,恶性肿瘤为14天。在对照患者中,仅对良性肿瘤检测到这些变化。在整个观察期内,在对照组中,良性瘤形成病例在10天之内,在恶性肿瘤病例在14天之内的严重疾病为背景,消除了实验组凝血的外部机制的转变。由于纤溶酶原激活物和组织纤溶酶原激活物在3-7天以相同的方式标准化,到10-14天总纤溶活性得以恢复,从而证实了复杂治疗方案的积极作用。在对照动物中,仅针对良性肿瘤的总纤维蛋白溶解活性与临床健康动物的一致。凝血和纤维蛋白溶解机制的平衡伴随着蛋白水解抑制剂活性的降低:在良性瘤形成的实验组中,第10天,恶性– 10 – 14天和对照组–第3和14天分别是α2-巨球蛋白;到第3天,所有组中的α1-蛋白酶抑制剂。术后第3天,在切除良性肿瘤后,所有组中一氧化氮的浓度与临床上健康的犬的指标相对应,在实验动物中,恶性肿瘤的去除率在第3天进行对照–在第14天。在药理校正的背景下,丙二醛和铜蓝蛋白的含量在第10-14天恢复,而在对照动物中–在第14天只有良性肿瘤恢复。止血系统的术后药理校正可以显着改善癌症患者的治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号